Drug Trial Radar · NCT04543617
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
760
Actual
Start
Sep 28, 2020
Primary completion
Jul 22, 2026
Study completion Jul 22, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (Arm A), tiragolumab matching placebo plus atezolizumab (Arm B), or double placebo (Arm C).
Conditions
- Esophageal Squamous Cell Carcinoma
Interventions
TiragolumabDrug
Tiragolumab at a fixed dose of 600 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
AtezolizumabDrug
Atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Tiragolumab Matching PlaceboDrug
Tiragolumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Atezolizumab Matching PlaceboDrug
Atezolizumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Arm A vs Arm C: Investigator-Assessed Progression-Free Survival (PFS)Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 6 years)
- Arm A vs Arm C: Overall Survival (OS)Time frame: From randomization to death from any cause (up to approximately 6 years)
- Arm B vs Arm C: OSTime frame: From randomization to death from any cause (up to approximately 6 years)
Locations
166 sites in 28 countries. Site status is shown where the registry gives one.
Florida Cancer Specialists - Fort Myers (Broadway)
Fort Myers, Florida
Cancer Center of Kansas
Wichita, Kansas
Great Lakes Cancer Center
Williamsville, New York
Instituto de Investigaciones Metabolicas (Idim)
Buenos Aires, Argentina
Fundacion Favaloro
Buenos Aires, Argentina
Centro Oncologico Riojano Integral (CORI)
La Rioja, Argentina
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Austin Health
Heidelberg, Victoria, Australia
St John of God Hospital
Subiaco, Western Australia, Australia
Tiroler Landeskrankenanstalten Ges.M.B.H.
Innsbruck, Austria
Klinikum Klagenfurt am Wörthersee
Klagenfurt, Austria
Ordensklinikum Linz Barmherzige Schwestern
Linz, Austria
AKH - Medizinische Universität Wien
Vienna, Austria
UZ Antwerpen
Edegem, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
CHU de Liège (Sart Tilman)
Liège, Belgium
Anyang Tumor Hosptial
Anyang, China
Cancer Hospital Chinese Academy of Medical Sciences.
Beijing, China
Affiliated Hospital of Bengbu Medical College
Bengbu, China
Hunan Cancer Hospital
Changsha, China
Heping Hospital Affiliated to Changzhi Medical College
Changzhi, China
Changzhou Cancer hospital
Changzhou, China
Sichuan Provincial Cancer Hospital
Chengdu, China
West China Hospital, Sichuan University
Chengdu, China
Chongqing Cancer Hospital
Chongqing, China
Chongqing Sanxia Central Hospital
Chongqing, China
Fujian Cancer Hospital
Fuzhou, China
Sun Yet-sen University Cancer Center
Guangzhou, China
Nanfang Hospital, Southern Medical University
Guangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Jieyang People's Hospital
Jieyang, China
Shandong Cancer Hospital
Jinan, China
Affiliated Hospital of Jining Medical University
Jining, China
The First People's Hospital of Lian Yun Gang
Lianyungang, China
Lishui Central Hospital
Lishui, China
The First Affiliated Hospital to Henan University of Science and Technology
Luoyang, China
Affiliated Drum Tower Hospital of Nanjing University Medical School
Nanjing, China
Shanghai Chest Hospital
Shanghai, China
Fudan University Shanghai Cancer Center
Shanghai, China
Cancer Hospital of Shantou University Medical College
Shantou, China
Showing 40 of 166 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.